.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Heart failure treatment costs in India are reaching a breaking point for many families across the country. Consequently, a recent nationwide study has highlighted a stark reality for those living with this chronic condition. Published in the journal Global Heart, the research reveals that seven out of 10 heart failure patients lack any form of financial protection. Therefore, most families are forced to bear the massive financial weight of medical care entirely from their personal savings.
On average, a patient in India spends more than ₹1 lakh annually on managing heart failure. Furthermore, the study indicates that over 90% of these expenses are paid directly by the patients. This high level of out-of-pocket spending exposes a significant gap in the Indian healthcare system regarding chronic illness support. Additionally, nearly one in three patients reported a substantial drop in their monthly earnings after diagnosis. Patients often stop working due to their health status, while family members frequently cut back on employment to provide necessary care. As a result, the financial burden is not limited to medical bills but extends to a loss of household income.
Approximately 38% of households affected by heart failure experience catastrophic health spending. Specifically, this means healthcare costs overwhelm the family's total capacity to pay for basic needs. Moreover, nearly one in six families must borrow money or sell their physical assets to sustain treatment. This economic distress often leads to poor clinical outcomes. When funds are low, patients frequently skip essential medications or delay follow-up appointments with their cardiologists. Consequently, these delays increase the risk of repeated hospitalisations, which are far more expensive than routine outpatient care. Therefore, addressing affordability is crucial for improving long-term survival rates in India.
Current insurance schemes, including Ayushman Bharat, primarily focus on hospitalisation and acute procedures. However, heart failure is a chronic disease that requires lifelong management and expensive medications. Most existing policies do not adequately cover the costs of outpatient visits, diagnostic tests, and daily drugs. Specifically, newer therapies have improved quality of life but remain unaffordable for the uninsured population. Expanding insurance to include structured follow-up care and long-term medication is essential. By providing better financial protection, the healthcare system can reduce the burden on rural and low-income families. Furthermore, this shift will likely improve patient adherence and reduce the overall national cost of heart failure management.
Q1: What is the average annual cost of heart failure treatment in India?
The average annual out-of-pocket cost for heart failure treatment in India is approximately ₹1.06 lakh. This figure accounts for nearly 93% of the total healthcare expenditure for most patients.
Q2: Why is current health insurance often insufficient for heart failure?
Most insurance schemes in India cover hospitalisation but fail to provide adequate support for outpatient care. Since heart failure requires lifelong medication and regular follow-ups, these uncovered costs create a massive financial strain.
Q3: How many patients in India are affected by catastrophic health spending?
Approximately 38% of heart failure patients in India face catastrophic health spending, often forcing them to borrow money or sell assets to afford their medical treatment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study finds 7 in 10 Indian heart failure patients lack insurance, with average annual costs exceeding ₹1 lakh, leading to catastrophic financial distress....
4 months ago
A 2026 meta-analysis evaluates PDE5 inhibitors in advanced ILD with severe gas exchange impairment. While overall mortality was not significantly reduced, a targeted subgroup with pulmonary hypertension showed a 49% risk reduction, underscoring the necessity of precise hemodynamic phenotyping.
Today
At the 79th Regional Committee session, the World Health Organization commended India's public health advancements. Key achievements include the operationalization of 160,000 Ayushman Arogya Mandirs, higher institutional delivery rates, strong ASHA networks, and persistent efforts to eliminate tuberculosis nationwide.
Today
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
